Download PDF
Der Nuklearmediziner 2003; 26(3): 155-159
DOI: 10.1055/s-2003-44330
Nuklearmedizinische Nierendiagnostik

© Georg Thieme Verlag Stuttgart · New York

Radiopharmaka für die Nierenfunktionsdiagnostik

Radiopharmaceuticals for Renal Function ImagingW. Brandau1
  • 1Klinik für Nuklearmedizin, Arbeitsgruppe Nuklearchemie und Radiopharmazie, Universitätsklinikum Essen
Further Information

Publication History

Publication Date:
20 November 2003 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

[99mTc] Technetium ist aufgrund seiner optimalen physikalischen Eigenschaften für die Bildgebung das meistverwendete Radionuklid in der Nuklearmedizin. Es kann aber nur in Form von Metallkomplexen eingesetzt werden, deren in vivo Verhalten schwer vorhersagbar ist. In den letzten Jahren ist es jedoch durch systematische Variation einer Leitstruktur gelungen, Technetium-Radiopharmaka zu entwickeln, die renal aktiv transportiert werden. Dadurch kann einerseits neben der Glomerulären Filtrationsrate nun auch die Tubuläre Extraktionsrate quantifiziert werden, andererseits ist erstmals die Szintigraphie mit Technetium-markierten Substanzen möglich, die tubulär sezerniert werden.

Abstract

Due to its favourable physical properties, [99mTc] Technetium is the mostly used radionuclide in nuclear medicine. It can only be used as metal complexes, whose pharmacokinetics cannot be predicted easily. By systematic variations of a known compound, Tc-complexes could be synthesized which are actively excreted by the kidneys. Thus, on the one hand, the tubular extraction rate can now be quantified in addition to the glomerular filtration rate and on the other hand, scintigraphic imaging is possible by the use of Tc-pharmaceuticals, which are eliminated by active tubular transport.

Schlüsselwörter

Tc-Radiopharmaka - Nierenfunktionsdiagnostika - Tc-MAG3 - Tc-DADS - Tc-EC

Key words

Tc-radiopharmaceuticals - renal function imaging agents - Tc-MAG3 - Tc-DADS - Tc-EC

Literatur

  • 1 Bianchi C, Blaufox M D. I-131-Hypaque and La-140-DTPA for the measurement of glomerular filtration in dog.  J Nucl med Biol Med. 1968;  12 117
    PubMedGoogle Scholar
  • 2 Bolt W, Lehnert G, Szadkowski D. Leberfunktionsprüfung mittels Radiodiodrast.  Med Klin. 1961;  56 1316
    PubMedGoogle Scholar
  • 3 Brandau W, Bubeck B, Eisenhut M, Steinbächer M, Georgi P, Reinbold F, Taylor D M. Preliminary Clinical Comparison of 99mTc-Mercaptoacetyl-triglycine and 131I-Orthoiodo-Hippuric Acid.  Nucl Med. 1986;  25 97-98
    PubMedGoogle Scholar
  • 4 Brandau W, Bubeck B, Eisenhut M, Taylor D M. Technetium-99m Labeled Renal Function and Imaging Agents: III. Synthesis of 99mTc MAG3 and Biodistribution of By-products.  Appl Radiat Isot. 1988;  19 121-129
    PubMedGoogle Scholar
  • 5 Bubeck B, Brandau W, Dreikorn K, Steinbächer M, Eisenhut M, zum Winkel K. Clinical Comparison of I-131 o-Iodohippurate with Tc-99m CO2-DADS-A and Tc-99m MAG3 by Simultaneous Double Tracer Measurement.  NucCompact. 1986;  17 135-138
    PubMedGoogle Scholar
  • 6 Bubeck B, Brandau W, Reinbold F, Dreikorn K, Steinbächer M, Eisenhut M, Georgi P. Technetium-99m Labeled Renal Function and Imaging Agents: I. Clinical Evaluation of 99mTc CO2-DADS-A (99mTc N,N′-Bis-(Mercaptoacetyl)-2,3-Diaminopropanoate).  Nucl Med Biol. 1988 a;  15 99-108
    PubMedGoogle Scholar
  • 7 Bubeck B, Brandau W, Steinbächer M, Reinbold F, Dreikorn K, Eisenhut M, Georgi P. Technetium-99m Labeled Renal Function and Imaging Agents: II. Clinical Evaluation of 99mTc MAG3 (99mTc Mercaptoacetylglycylglycylglycine).  Nucl Med Biol. 1988 b;  15 109-118
    PubMedGoogle Scholar
  • 8 Bubeck B, Brandau W, Weber E, Kälble T, Parekh N, Georgi P. Pharmakokinetics of Technetium-99m-MAG3 in Humans.  J Nucl Med. 1990;  31 1285-1293
    PubMedGoogle Scholar
  • 9 Bubeck B. Technetium-99m-MAG3 für die nuklearmedizinische Nierenfunktionsdiagnostik. Huber, Bern, Göttingen, Toronto, Seattle 1993
    Google Scholar
  • 10 Burbank M K, Tauxe W N, Maher F T, Hunt J C. Evaluation of radioiodinated hippuran for the estimation of renal plasma flow.  Mayo Clin Proc. 1961;  36 372-386
    PubMedGoogle Scholar
  • 11 Chassis H, Redish W, Goldring W. et al . The use of sodium p-aminohippurate for the functional evaluation of the human kidney.  J Clin Invest. 1945;  24 583-588
    PubMedGoogle Scholar
  • 12 Davison A, Sohn M, Orvig C, Jones A G, LaTegola M R. A tetradentate ligand designed specifically to coordinate technetium.  J Nucl Med. 1979;  20 641
    PubMedGoogle Scholar
  • 13 Davison A, Jones A G, Orvig C, Sohn M. A New Class of Oxotechnetium(5+)Chelate Complexes Containing a TcON2S2 Core.  Inorg Chem. 1981;  20 1629-1632
    CrossrefPubMedGoogle Scholar
  • 14 Despopoulos A. A definition of substrate specifity in renal transport of organic anions.  J Theoret Biol. 1965;  8 163-192
    PubMedGoogle Scholar
  • 15 Dubovsky E V, Russell C D. 99mTc-MAG3: The Multipurpose Renal Radiopharmaceutical. In: Freeman LM. Nuclear Medicine Annual, Raven Press, New York 1991; 1-34
    Google Scholar
  • 16 Elwood C M, Sigman E M. The measurement of glomerular filtration and effective renal plasma flow in man by iothalamate-I131 and iodopyracet-I131.  Circulation. 1967;  36 441
    PubMedGoogle Scholar
  • 17 Eshima D, Fritzberg A R, Taylor A. 99mTc Renal Tubular Function Agents: Current Status.  Sem Nucl Med. 1990;  XX 28-40
    PubMedGoogle Scholar
  • 18 Fritzberg A R, Klingensmith W C, Whitney W P, Kuni C C. Chemical and Biological Studies of Tc-99m N,N′-Bis(mercaptoacetamido)ethylenediamine: A Potential Replacement for I-131 Iodohippurate.  J Nucl Med. 1981;  22 158-263
    PubMedGoogle Scholar
  • 19 Fritzberg A R, Whitney W P, Kuni C C, Klingensmith W C. Biodistribution and Renal Excretion of 99mTc-N,N′-bis-(Mercaptoacetamido) Ethylenediamine. Effect of Renal Tubular Transport Inhibitors.  Int J Med Biol. 1982 a;  9 79-82
    PubMedGoogle Scholar
  • 20 Fritzberg A R, Kuni C C, Klingensmith W C, Stevens J, Whitney W P. Synthesis and Biological Evaluation of Tc-99m N,N′-Bis(mercaptoacetyl)-2,3-diaminopropanoate: A Potential Replacement for [131I] o-iodohippurate.  J Nucl Med. 1982 b;  23 592-598
    PubMedGoogle Scholar
  • 21 Fritzberg A R, Kasina S, Johnson D L, Eshima D. Triamide Mercaptide (N 3S) Ligands for Tc-99m as Potential Tc-99m Renal Function Agents.  J Nucl Med. 1985;  26 19
    PubMedGoogle Scholar
  • 22 Fritzberg A R, Kasina S, Eshima D, Johnson D L. Synthesis and Biological Evaluation of Technetium-99m MAG3 as a Hippuran Replacement.  J Nucl Med. 1986;  27 111-116
    PubMedGoogle Scholar
  • 23 Johannsen B, Noll B, Heise K-H, May K, Syhre R, Strangfeld D, Bruch L, Modersohn D. Chemical and biological studies on the Technetium/S-unprotected MAG 3-System.  Med nucl. 1990;  2 115-123
    PubMedGoogle Scholar
  • 24 Jones A G, Davison A, LaTegola M R, Brodack W, Orvig C, Sohn M, Toothaker A K, Lock C JL, Franklin J, Costello C E, Carr S A, Biemann K, Kaplan M L. Chemical and In Vivo Studies of the Anion oxo[N,N′-ethylenebis(2-mercaptoacetimido)]Technetate(V).  J Nucl Med. 1982;  23 801-809
    PubMedGoogle Scholar
  • 25 Kasina S, Fritzberg A R, Johnson D L, Eshima D. Tissue Distribution Properties of Technetium-99m-Diamide-Dimercaptide Complexes and Potential Use as Renal Radiopharmaceuticals.  J Med Chem. 1986;  29 1933-1940
    CrossrefPubMedGoogle Scholar
  • 26 Kimbel K H, Börner W. Über den Verbleib von J131-markiertem Urografin im Körper.  Nauyn-Schmiedebergs Arch Exp Path Pharmakol. 1955;  226 262-268
    PubMedGoogle Scholar
  • 27 Klingensmith W C, Fritzberg A R, Spitzer V M, Johnson D L, Kuni C C, Williamson M R, Washer G, Weil R. Clinical Evaluation of Tc-99m N,N′-Bis(mercaptoacetyl)-2,3-Diaminopropanoate as a Replacement for I-131 Hippurate: Concise Communication.  J Nucl Med. 1984;  25 42-48
    PubMedGoogle Scholar
  • 28 Lippman R W, Finkle R D, Gilette D. Effect of proteinuria on localization of radiomercury in rat kidney.  Proc Soc Exp Biol Med. 1951;  77 68
    PubMedGoogle Scholar
  • 29 Maher F T, Tauxe W N. Renal clearance in man of pharmaceuticals containing radioactive iodine. Influence of plasma binding.  JAMA. 1969;  207 97-104
    CrossrefPubMedGoogle Scholar
  • 30 McAfee J G, Subramanian G, Schneider R F, Roskopf M, Lyons B, Ritter C, Zapf-Longo C, Palladino E, Thomas F D. Technetium-99m DADS Complexes as Renal Function and Imaging Agents: II. Biological Comparison with Iodine-131 Hippuran.  J Nucl Med. 1985;  26 375-386
    PubMedGoogle Scholar
  • 31 Nordyke R A, Tubis M, Blahd W H. Use of radioiodinated hippuran for individual kidney function test.  J Lab Clin Med. 1960;  56 438-445
    PubMedGoogle Scholar
  • 32 Oeser H, Billion H. Funktionelle Strahlendiagnostik durch etikettierte Röntgenkontrastmittel.  Fortschr Röntgenstr. 1952;  76 431-442
    PubMedGoogle Scholar
  • 33 Schneider R F, Subramanian G, Feld T A, McAfee J G, Zapf-Longo C, Palladino E, Thomas F D. N,N′-bis(S-Benzoylmercaptoacetamido)Ethylenediamine and Propylenediamine Ligands as Renal Function and Imaging Agents. I. Alternate Synthetic Methods.  J Nucl Med. 1984;  25 223-229
    PubMedGoogle Scholar
  • 34 Smith H W, Finkelstein N, Aliminosa L M. et al . Renal clearances of substituted hippuric acid derivatives and other aromatic acids in dogs and man.  J Clin Invest. 1945;  24 388-404
    CrossrefPubMedGoogle Scholar
  • 35 Taplin G V, Meredith O M, Kade H, Winkler C C. The radioisotope renogram: an external test for individual kidney function and upper urinary tract patency.  J Lab Clin Med. 1956;  48 886-901
    PubMedGoogle Scholar
  • 36 Taylor A, Eshima D, Fritzberg A R, Christian P E, Kasina S. Comparison of Iodine-131 OIH and Technetium-99m MAG3 Renal Imaging in Volunteers.  J Nucl Med. 1986;  27 795-803
    PubMedGoogle Scholar
  • 37 Taylor A, Hansen L, Eshima D, Malveaux E, Folks R, Shattuck L, Lipowska M, Marzilli L G. Comparison of Technietium-99m-LL-EC Isomers in Rats and Humans.  J Nucl Med. 1997;  38 821-826
    PubMedGoogle Scholar
  • 38 Threefoot S A, Ray C T, Burch G E, Cronvich J A, Milnor J P, Overman W, Gordon W. Concentration-time course in the plasma of a man of radiomercury introduced as mercurail diuretic.  J Clin Invest. 1949;  28 661
    PubMedGoogle Scholar
  • 39 Tubis M, Posnick E, Nordyke R A. Preparation and use of I-131 labeled sodium iodohippurate in kidney function tests.  Proc Soc Exp Biol Med. 1960;  103 497-498
    PubMedGoogle Scholar
  • 40 Van Nerom C G, Bormans G M, De Roo M J, Verbruggen A M. First experience in healthy vounteers with technetium-99m L,L-ethylenedicysteine, a new renal imaging agent.  Eur J Nucl Med. 1993;  20 738-746
    PubMedGoogle Scholar
  • 41 Verbruggen A M, Nosco D L, Van Nerom C G, Bormans G M, Adiaens P J, De Roo M J. Technetium-99m-L,L-Ethylenedicysteine: A Renal Imaging Agent: I. Labeling and Evaluation in Animals.  J Nucl Med. 1992;  33 551-557
    PubMedGoogle Scholar
  • 42 Wellman H N, Berke R A, Robbins P J, Anger R T. Dynamic quantitative renal imaging with 123I-hippuran - a possible salvation of the renogram.  J Nucl Med. 1971;  12 405-406
    PubMedGoogle Scholar
  • 43 Winter C C. A clinical study of a new renal function test: the radioactive diodrast renogram.  J Urol. 1956;  76 182
    PubMedGoogle Scholar

Prof. Dr. W Brandau

Universitätsklinikum Essen

Nuklearchemie und Radiopharmazie

Hufelandstr. 55

D-45122 Essen

Phone: +49-2 01/7 23-41 72

Fax: +49-2 01/7 23-59 32

Email: Wolfgang.brandau@uni-essen.de

      >